Merck
CN
  • Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses.

Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses.

The Journal of pharmacy and pharmacology (2002-10-03)
Zhengrong Cui, Russell J Mumper
ABSTRACT

Intranasal immunization offers potential forthe elicitation of effective mucosal and systemic immune responses. In this study, a previously reported novel cationic nanoparticle engineered from a microemulsion precursor was further modified, optimized and applied intranasally to mice to explore its potential as a plasmid DNA (pDNA) vaccine delivery system. To this end, more uniform nanoparticles (around 100 nm) containing less cationic surfactant were developed. The pDNA-coated nanoparticles significantly enhanced the specific serum IgG and IgA titres to an expressed model antigen, beta-galactosidase, by 18-28 and 25-30 fold, respectively, when compared with naked pDNA alone. An enhanced splenocyte proliferative response was also observed after immunization with the pDNA-coated nanoparticles. It was concluded that these plasmid DNA-coated nanoparticles may have potential for immunization via the nasal route.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Brij® S 100, average Mn ~4,670
Sigma-Aldrich
Brij® S20
Sigma-Aldrich
Brij® S10, average Mn ~711
Sigma-Aldrich
SP Brij® S2 MBAL, main component: diethylene glycol octadecyl ether
Sigma-Aldrich
ECO Brij® S20
Sigma-Aldrich
ECO Brij® S100, average Mn ~4,670
Sigma-Aldrich
ECO Brij® S10, average Mn ~711